Barchart6d agoneutral
Why DataMEDS’ Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This PointThe low purchase price of Helomics and low revenue suggest that the acquisition is not that promising for DataMEDS AI.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
135last 24h
869last 7d
144● bullish (7d)
99● bearish (7d)
214publishers
MarketBeat49d agoneutral
Schrodinger Q2 Earnings Call HighlightsSchrodinger (NASDAQ:SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist. Second-quarter
Moby141d agoneutral
Schrödinger, Inc. Q1 2026 Earnings Call SummaryMoby summary of Schrödinger, Inc.'s Q1 2026 earnings call
MarketBeat141d agoneutral
Schrodinger Q1 Earnings Call HighlightsSchrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti